Research Topics
Genomes and Genes | Rogier W SandersSummaryAffiliation: Academic Medical Center Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
HIV takes double hit before entryRogier W Sanders
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
BMC Biol 10:99. 2013..In contrast to traditional drugs that inhibit essential steps in the viral life cycle at the cell surface or in the infected cells, this inhibitor cripples free virus in the absence of cells...- A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cellsMark Melchers
Laboratory of Experimental Virology, Department of Medical Microbiology Center for Infection and Immunity Amsterdam, Netherlands
Retrovirology 8:48. 2011..We have previously stabilized soluble trimeric mimics of Env by introducing a disulfide bond between gp120 and gp41 and adding a trimer stabilizing mutation in gp41 (SOSIP.R6 gp140)... - Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bondRogier W Sanders
Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
Mol Biol Cell 19:4707-16. 2008..Our results show that the interactions between two beta-strands that are important for the formation and/or integrity of the beta-barrel can be supported by either a disulfide bond or beta-sheet favoring residues... 
Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccineRogier W Sanders
Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam The Netherlands
Expert Rev Vaccines 10:1117-20. 2011..They found that the vaccine was safe and induced neutralizing antibody responses against the homologous virus, but not cross-neutralizing responses. The results reinforce the notion that our Env vaccine design needs to improve...- The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasionRogier W Sanders
Laboratory of Experimental Virology, Dept, Medical Microbiology, Center of Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
Retrovirology 5:10. 2008..Here we studied the role of the carbohydrate at position 386. We identified a virus variant that had lost the 386 glycan in an evolution study of a mutant virus lacking the disulfide bond at the base of the V4 domain... - Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41Rogier W Sanders
Dept of Human Retrovirology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
Retrovirology 1:3. 2004..The modified Env protein antigenically mimics the functional wild-type Env complex. Here, we explore the effects of the covalent gp120 - gp41 interaction on virus replication and evolution... - Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitorsDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Biol Chem 284:26941-50. 2009..Implications for the design of novel antiviral peptide inhibitors are discussed... - Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolutionIlja Bontjer
Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Biol Chem 285:36456-70. 2010..These evolved ΔV1V2 trimers could be useful reagents for immunogenicity and structural studies... - HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentationThijs van Montfort
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Immunol 187:4676-85. 2011..This finding may have implications for the early events in HIV-1 transmission and the induction of antiviral immune responses... - Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interactionFedde Groot
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
J Virol 79:3009-15. 2005..DC-mediated capture of a bLF-resistant HIV-1 variant that was selected during long-term culturing in T cells could still be blocked by bLF. This underscores the usefulness of bLF as a microbicide drug to prevent HIV-1 transmission... - Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structureRogier W Sanders
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, The Netherlands
AIDS Res Hum Retroviruses 20:742-9. 2004..In the escape virus, which contains a Pro559Leu first-site pseudoreversion, the local helical structure and, as a consequence, Env biosynthesis and function are restored... - Selection of T1249-resistant human immunodeficiency virus type 1 variantsDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
J Virol 82:6678-88. 2008..Furthermore, substitutions at position 38 do not provide resistance to the third-generation inhibitor T2635, while substitution at positions 79 and 90 do, suggesting different resistance mechanisms... - Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolutionIlja Bontjer
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center, University of Amsterdam, Meibergdreef 15 K3 105, 1105 AZ Amsterdam, The Netherlands
J Virol 83:368-83. 2009..In general, virus evolution may provide a powerful tool to optimize Env vaccine antigens... 
Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytesMartijn J Stax
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
Virology 391:203-11. 2009..Additionally, we demonstrate that purified mucin 6 binds DC-SIGN and successfully inhibits viral transfer. Mucin 6 in seminal plasma may therefore interfere with the sexual transmission of HIV-1 and other DC-SIGN co-opting viruses...- Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
J Virol 85:10785-97. 2011..It requires the accumulation of multiple mutations in gp41, is accompanied with a dramatic loss of gp41 function, and induces compensatory mutations in gp120... - Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responsesMark Melchers
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, University of Amsterdam, The Netherlands
J Virol 86:2488-500. 2012..Targeting and activating B cells with a trimeric HIV-1 Env-APRIL fusion protein may therefore improve the induction of humoral immunity against HIV-1... - Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry functionDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
Virology 401:236-47. 2010..Manipulating Env's N-glycosylation may be useful for structural and functional studies and for vaccine design... - Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entryFedde Groot
Department of Human Retrovirology, Academic Medical Center, Meibergdreef 15, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Virol 80:9236-43. 2006..This study shows that modification of antimicrobial peptides in order to improve their activity against a pathogen may have unpredictable and unwanted side effects on other pathogens... - Dendritic Cell-induced Activation of Latent HIV-1 Provirus in Actively Proliferating Primary T LymphocytesRenee M van der Sluis
Laboratory of Experimental Virology, Department of Medical Microbiology, Centre for Infection and Immunity Amsterdam CINIMA, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
PLoS Pathog 9:e1003259. 2013..Unraveling this physiologically relevant purging mechanism could provide useful information for the development of new therapeutic strategies that aim at the eradication of HIV-1 reservoirs... - Inhibition of HIV-1 by fusion inhibitorsDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
Curr Pharm Des 16:3716-28. 2010..Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens... - Antibodies to HIV-1: aiming at the right targetDirk Eggink
Laboratory of Experimental Virology, Department of Medical Microbiology, Center of Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, The Netherlands
Trends Microbiol 15:291-4. 2007..We discuss these observations and explain their relevance for HIV-1 vaccine design... - Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificityRenee M van der Sluis
Laboratory of Experimental Virology, Department of Medical Microbiology, Centre for Infection and Immunity Amsterdam, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, Amsterdam, The Netherlands
J Virol Methods 187:94-102. 2013..Execution of the pre-amplification step with a second primer set enables for the exclusive quantitation of the 2-LTR circular HIV-1 DNA form... - A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responsesThijs van Montfort
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Biol Chem 286:22250-61. 2011..Collectively, these results show that targeting and activation of immune cells using engineered cytokine domains within the protein can improve the immunogenicity of Env subunit vaccines... - Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitorChris E Baldwin
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
J Virol 78:12428-37. 2004..A premature switch will generate nonfunctional envelope glycoproteins (dead spikes) on the surface of the virion, and T20 prevents this abortive event by acting as a safety pin that preserves an earlier prefusion conformation... - Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Rogier W Sanders
Department of Microbiology and Immunology, Weill Medical College, Cornell University, New York, New York 10021, USA
J Virol 76:8875-89. 2002..SOSIP gp140 should be a useful reagent for structural and immunogenicity studies... - Selective packaging of cellular miRNAs in HIV-1 particlesNick C T Schopman
Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
Virus Res 169:438-47. 2012..A small subset of the cellular miRNAs is dramatically concentrated in the virions up to 115 fold, suggesting a biological function in HIV-1 replication... - Broadly neutralizing antibodies against HIV-1: templates for a vaccineMarit J van Gils
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands
Virology 435:46-56. 2013..Here we will review the characteristics of the different classes of BrNAbs and their target epitopes, as well as factors associated with their development and implications for vaccine design... - Is there a future for antiviral fusion inhibitors?Ben Berkhout
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, The Netherlands
Curr Opin Virol 2:50-9. 2012..Here, we will review the field of HIV-1 fusion inhibitors... - Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteinsJames M Binley
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
J Virol 76:2606-16. 2002..Coexpression of Env cleavage site mutants and furin is therefore a useful method for obtaining high-level expression of processed Env... - Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120Thijs van Montfort
Department of Medical Microbiology, Laboratory of Experimental Virology, Academic Medical Center of the University of Amsterdam, The Netherlands
Expert Rev Vaccines 11:1175-7. 2012..These results demonstrate that optimal induction of antiviral CD8(+) responses requires careful optimization of vaccine design, composition and administration... - Chimeric HIV-1 Envelope Glycoproteins with Potent Intrinsic Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Activity*Gözde Isik
Department of Medical Microbiology, Laboratory of Experimental Virology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
PLoS ONE 8:e60126. 2013..Chimeric EnvGM-CSF should be useful for improving humoral immunity against HIV-1 and these studies should inform the design of other chimeric proteins... - Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cellsRogier W Sanders
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
J Virol 76:7812-21. 2002..The ICAM-1-LFA-1 interaction is known to be important for immunological cross talk between DC and T cells, and our results indicate that this cell-cell contact is exploited by HIV-1 for efficient transmission... - Molecular strategies to design an escape-proof antiviral therapyBen Berkhout
Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, The Netherlands
Antiviral Res 92:7-14. 2011..Several options for a combinatorial RNAi attack to prevent viral escape will be discussed. The simultaneous use of multiple RNAi inhibitors turns out to be the most effective and durable strategy... - Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Simon Beddows
Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Ave, Room W-805, New York, NY 10021, USA
J Virol 79:8812-27. 2005..Neutralization of these viruses was immunoglobulin mediated and was predominantly caused by antibodies to gp120 epitopes, but not the V3 region... - IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccinesKaustuv Banerjee
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, USA
AIDS Res Hum Retroviruses 26:445-58. 2010..Although we found isotypic differences in IgG responses to HIV-1 antigens among vaccinees and the HC and CP individuals, there were no indications of differential T(H)1:T(H)2 polarization between the different groups... - Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryReem Berro
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America
PLoS Pathog 5:e1000548. 2009..However, D1/86.16 cl.23 does not have an increased dependency on the CCR5 N-terminus, and its CCR5 binding site has not become more exposed. How this virus interacts with the inhibitor-CCR5 complex remains to be understood... - Gene therapy as a vaccine for HIV-1Ben Berkhout
University of Amsterdam, Center for Infection and Immunity Amsterdam, Academic Medical Center, Department of Medical Microbiology, Laboratory of Experimental Virology, Meibergdreef 15, K3 110, 1105 AZ Amsterdam, The Netherlands
Expert Opin Biol Ther 12:1315-21. 2012..EXPERT OPINION: VIP is a prolonged form of passive immunization by means of a gene therapy. We will discuss the ins and outs of VIP and the therapeutic possibilities and challenges... - Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivoKaustuv Banerjee
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA
Virology 389:108-21. 2009..Giving an IL-10 receptor blocking MAb together with unmodified gp120 in Alum increased the anti-gp120 IgG titer, implicating IL-10 as a possible mediator of auto-suppressive responses to gp120... - The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120Rogier W Sanders
Dept of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
J Virol 76:7293-305. 2002.... - HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cellsMeimei Shan
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America
PLoS Pathog 3:e169. 2007..Since such mechanisms might suppress immune responses to Env-containing vaccines, demannosylation may be a way to improve the immunogenicity of gp120 or gp140 proteins... - HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduitsWeifeng Xu
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York, USA
Nat Immunol 10:1008-17. 2009....